) extended-release oral formulation, Xartemis XR (oxycodone HCI
and acetaminophen) gained U.S. Food and Drug Administration (FDA)
approval for the management of acute pain in patients requiring
opioid treatment and for whom alternative therapies are
inadequate, ineffective or are not tolerated.
Meanwhile, Mallinckrodt is conducting additional studies and
working closely with the FDA to generate more data on Xartemis
XR. Although the label does not contain abuse-deterrent language,
Mallinckrodt is looking to provide more data on Xartemis XR's
Xartemis XR is the first and only approved extended-release
oral combination of oxycodone HCI and acetaminophen. The company
intends to launch Xartemis XR in the second quarter of fiscal
2014. We remind investors that Mallinckrodt recently launched
another pain drug, Pennsaid 2%, for the treatment of
osteoarthritis pain of the knees.
Mallinckrodt is actively focusing on strengthening its
pipeline and promoting new products in the pain market. The
company expects to file for approval of another pain candidate,
MNK-155, in the second half of fiscal 2014.
Meanwhile, Mallinckrodt announced its intention to acquire
Cadence Pharmaceuticals, Inc.
) for about $1.3 billion. With this acquisition, Mallinckrodt is
looking to strengthen its specialty pharma segment. Given Cadence
Pharma's strong presence in the hospital market, this acquisition
will add another potential growth area for Mallinckrodt.
Currently, Mallinckrodt carries a Zacks Rank #1 (Strong Buy).
Other stocks looking equally good in the health care sector are
Dr. Reddy's Laboratories Ltd.
). While Dr. Reddy's Lab holds a Zacks Rank #1 (Strong Buy),
Actavis carries a Zacks Rank #2 (Buy).
ACTAVIS PLC (ACT): Free Stock Analysis Report
CADENCE PHARMA (CADX): Free Stock Analysis
MALLINCKRODT PL (MNK): Free Stock Analysis
DOCTOR REDDYS (RDY): Free Stock Analysis
To read this article on Zacks.com click here.